Advancement in Abuse-Deterrent Opioids with Paul Howe Protega Pharmaceuticals TRANSCRIPT

Paul Howe, COO of Protega Pharmaceuticals, is focused on how abuse-deterrent technology can address the opioid crisis and the need for mandates for insurance coverage of safer abuse-deterrent formulations. The SentryBond technology was specifically designed for immediate-release opioids to make it difficult to manipulate pills for abuse via crushing, inhaling, or injecting. Protega partnered with software company Opus to offer a program that helps educate chronic pain patients, manage their treatment, and provides physicians with risk stratification data to improve care and reduce the likelihood of abuse.

Paul explains, "Most importantly from our standpoint is to protect from the risk of misuse, abuse, and diversion, which is escalation from orally taking medications to crushing, inhaling, injecting, or smoking. Unfortunately, when that escalation happens, many times patients end up on illicit fentanyl and heroin through the black market. So what we're trying to do is stop that escalation through our abuse deterrent technology and our medication. It's called SentryBond abuse deterrent technology, the company's Protega Pharmaceuticals."  

"We also have a software program that we're now offering to physicians that deal and work with a lot of patients with chronic pain that really helps patients with chronic pain understand how to treat their pain and also titrate down off medications when possible, or at least get on the lowest possible dose and try multimodal care, try other types of avenues of procedures, different things they can do to help with their chronic pain."

#ProtegaPharmaceuticals #PainManagement #ChronicPain #OpioidAbuse #OpioidPolicy #AbuseDeterrent.

protegapharma.com

Listen to the podcast here